Jimenez vows Novartis-wide GMP standard; Catalent expands in Germany;

> "We are committed to ensuring one single high quality standard across Novartis and will invest the necessary resources to achieve this goal in all divisions," said Novartis ($NVS) CEO Joe Jimenez in a financial filing. Story

> Catalent Pharma said it is expanding its Schorndorf, Germany facility, adding R&D and commercial-scale fluid bed technology, OptiMelt hot-melt extrusion and cGMP compliance upgrades. Release

> CMO Patheon has elevated Antonella Mancuso to president, global commercial operations and chief manufacturing officer. Release

> The FDA has added Tromethamine, made by Hospira ($HSP), to the list of resolved drug shortages. Listing.

> Supply chain industry group GS1 is readying a pilot project in Thailand for use of bar codes on nutritional ingredients. Story

> The DEA has registered AMPAC Fine Chemicals as a manufacturer of controlled substances. Article

> Washington state pharmacies were raided by federal officials on suspicion they were reselling drugs that had been returned. Story

> Thin Film Electronics and PST Sensors will collaborate to develop a printed sensor system that monitors the temperature of in-transit pharmaceuticals and foods. Article

 

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.